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Abstract 
Accurate prediction of sudden cardiac death due to ventricular arrhythmia remains 
challenging. Left ventricular ejection fraction has shown an association with increased risk of 
ventricular arrhythmias and is included in the recommendations for implantable cardioverter 
defibrillator as primary prevention. However, left ventricular ejection fraction may be 
normal in a large number of patients who are risk of ventricular arrhythmias. 
Echocardiography remains the imaging technique of first choice to rule out the presence of 
structural heart disease and assess left and right ventricular function. Advances in strain 
echocardiography and cardiac magnetic resonance have provided important insights into the 
mechanisms of ventricular arrhythmias and will be summarized in this review.   
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Abbreviations: 
ARVC  arrhythmogenic right ventricular cardiomyopathy 
CI  confidence interval 
CMR  cardiac magnetic resonance 
GLS  global longitudinal strain 
HR  hazard ratio 
ICD  implantable cardioverter defibrillator 
LGE  late gadolinium enhancement 
LV  left ventricular 
LVEF  left ventricular ejection fraction 
SCD  sudden cardiac death  
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INTRODUCTION  
Accurate prediction of sudden cardiac death (SCD) due to ventricular arrhythmia remains 
challenging. Predictive models should take into consideration the interaction between 
vulnerable substrates, defined by the presence of genetic or acquired electrical, functional 
or structural heart disease, and the multiple transient factors (such as ischemia, 
catecholamine or electrolyte dysregulations) that may precipitate the ventricular 
arrhythmia, making almost impossible to obtain one common predictive model for all 
patients, including individuals without known heart disease.  Of the total number of SCD 
events, almost 50% occur in subjects without known heart disease.1 However, many of those 
individuals have subclinical coronary artery disease and accordingly, risk-profiling strategies 
that promote preventive and life-style modification therapies that reduce the risk of 
coronary artery disease have been encouraged.2 In patients with known ischemic heart 
disease and dilated cardiomyopathy, left ventricular ejection fraction (LVEF) has consistently 
shown an association with increased risk of ventricular arrhythmias and therefore, this 
variable is included in the recommendations for implantable cardioverter defibrillator (ICD) 
as primary prevention (class I).3 However, one third of these patients do not develop 
ventricular arrhythmias after ICD implantation.4 Finally, in patients with inheritable 
arrhythmogenic diseases, LVEF may be preserved in a large majority of patients and other 
variables such as duration of the corrected QT interval (in long QT syndrome), 
interventricular septum thickness (in hypertrophic cardiomyopathy) or right ventricular 
aneurysms (in arrhythmogenic dysplasia of the right ventricle) have been included in the 
predictive models.3  
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Cardiac imaging has developed several indices beyond LVEF that permit the identification of 
patients at high risk for SCD. Echocardiography remains the imaging technique of first choice 
to rule out the presence of structural heart disease and assess left and right ventricular 
function. Advances in strain imaging have provided important insights into the dispersion of 
the mechanical activation throughout the left ventricle and the presence of heterogeneous 
regional function that may increase the risk of ventricular arrhythmias.5-8 Furthermore, 
cardiac magnetic resonance (CMR) is currently considered the reference standard for the 
measurement of the cardiac chamber dimensions and function and provides the unique 
opportunity of non-invasive myocardial tissue characterisation by identifying the presence 
and extent of myocardial oedema/inflammation, as well as focal, replacement and 
interstitial myocardial fibrosis which can be a substrate for arrhythmia.   
This review article provides an overview on current evidence showing the additional role of 
advanced echocardiography and CMR techniques to select patients for ICD implantation for 
primary prevention. Several echocardiographic and CMR-derived parameters characterizing 
the arrhythmogenic substrate and transient factors that may increase arrhythmogenicity in 
ischemic and non-ischemic cardiomyopathies will be reviewed. 
 
Ischemic cardiomyopathy  
In ischemic cardiomyopathy, the most frequent underlying mechanism of ventricular 
arrhythmia/fibrillation is re-entry. The presence of unexcitable dense scar tissue (core 
infarct) forms an area of fixed conduction block whereas the surrounding areas with viable 
myocardium intermingled with fibrous tissue (border or peri-infarct zone) increase the non-
uniform anisotropy, favours electrical uncoupling and leads to areas of unidirectional 
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conduction block and slow conduction forming the substrate for re-entry.9 Ischemia acts as a 
trigger of re-entry by enhancing the electrical heterogeneity of the tissue, prolonging the 
duration of the action potential, influencing the calcium handling and myocyte membrane 
properties, reducing the cellular coupling and inducing redistribution of connexines.9 
Furthermore, sympathetic innervation plays a role in the development of ventricular 
arrhythmias and it has been shown that patients with ischemic heart disease and large 
mismatch between the denervated ventricular myocardium and viable myocardium have 
high risk of ventricular arrhythmic events.9 Although, LVEF remains the main parameter to 
consider ischemic heart failure patients for ICD in primary prevention, it does not reflect the 
complexity of the arrhythmogenic substrate and transient factors that may trigger the 
arrhythmias. While late-gadolinium contrast-enhanced (LGE) CMR provides high-spatial 
resolution data to characterize the infarct tissue and the components of the arrhythmogenic 
substrate (infarct core and border zone), several advanced echocardiographic parameters 
that characterize the functional properties of that substrate and have been associated with 
the increased risk of ventricular arrhythmias, have been proposed (Table 1).   
In patients with myocardial infarction, gadolinium-based contrast agents accumulate in the 
increased extracellular space with a subendocardial or transmural distribution within the left 
ventricular wall reflecting the ischemic-necrotic wave-front phenomenon during myocardial 
infarction. On T1-weighted CMR acquisitions, myocardial scarring appears hyperintense 
(white) in contrast to the normal viable myocardium (Figure 1). Detection and quantification 
of myocardial fibrosis with LGE CMR has been associated with the occurrence of ventricular 
arrhythmias in patients with ischemic heart disease.10-15 Scott et al demonstrated in 64 
patients with known coronary artery disease who underwent LGE CMR prior to ICD 
implantation that an increasing number of LV segments with transmural myocardial 
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infarction was associated with increased risk of having appropriate ICD shock during follow-
up (HR 1.48, 95% CI 1.18-1.84, p=0.001) whereas LVEF was not.15 Furthermore, based on 
different thresholds of signal intensity compared to normal myocardium (lowest signal) or 
the infarct core (highest signal), the tissue heterogeneity of the scarred myocardium can be 
assessed with LGE CMR. The border or peri-infarct zone shows characteristically lower signal 
intensity than the infarct core but higher than the normal myocardium. This tissue 
heterogeneity has been associated with the occurrence of ventricular arrhythmias.13, 14 In 91 
ischemic heart failure patients receiving an ICD, each 10 g increase in peri-infarct zone was 
independently associated with the occurrence of ventricular arrhythmias (HR 1.49, 95% CI 
1.01-2.20; p=0.04) whereas LVEF and total infarct size were not associated.13 In addition, the 
analysis of the peri-infarct zone with LGE CMR permits the identification of conduction 
channels (critical isthmus of most ventricular arrhythmias), having important implications for 
ablation of ventricular tachycardia.16, 17 These channels consist of bundles of viable 
myocardium surrounded by compact scar tissue that connect with normal myocardium by at 
least one side of the of the scar and have characteristically a lower signal intensity than the 
infarct core on LGE CMR images. These structures have been more frequently identified in 
patients with ischemic cardiomyopathy and ventricular arrhythmias as compared with 
patients without arrhythmias (88% vs. 33%, pp<0.001).17 The 3-dimensional reconstruction 
of the myocardial scar can be merged with electroanatomical mapping and facilitate the 
ablation procedures by non-invasively visualizing the critical isthmus.16 
The electrophysiological properties of the myocardial scar may change over time and may be 
influenced by changes in the composition of the extracellular matrix or the presence of 
ischemia.18, 19 For example, the presence of iron deposition in myocardial infarction has been 
associated with prolongued inflammation, long corrected QT interval, isolated late potentials 
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and LV remodeling.20 Iron deposits are visualized on balanced steady-state free precession 
CMR sequences as hypointense cores and have been shown to provide incremental value to 
LVEF to predict ventricular arrhythmias (area under the curve 0.68 for LVEF alone, 0.87 for 
LVEF + hypointense cores).18 Furthermore, vasodilator stress CMR perfusion demonstrated 
the complementary prognostic value of reversible perfusion defects (ischemia) to the 
presence of LGE.19 In 254 patients with suspected or known coronary artery disease (22% 
with prior myocardial infarction), the presence of reversible perfussion defects was 
associated with a 3-fold increased risk of cardiac death after adjusting for presence of LGE, 
age and gender.19 
Advanced echocardiography can also assess the tissue heterogeneity of myocardial 
infarction focusing on the mechanical and electrical properties. Echocardiographic speckle 
tracking analysis informs about the deformational capacity of the LV myocardium, 
representing the contractile status of the myocardium. The 3-dimensional disposition of the 
myocardial fibers changing continuously from a right-handed helix in the sub-endocardium 
to a left-handed helix in the subepicardium determines the specific deformation of the left 
ventricle: shortening-lengthening in the longitudinal and circumferential directions and 
thickening-thinning in the radial direction.21 Myocardial infarction will alter this disposition 
by the deposition of collagen fibers, scar formation and remodeling increasing the functional 
heterogeneity of the myocardial tissue of the core infarct, the peri-infarct and the remote 
zone. The magnitude of global and regional LV longitudinal strain assessed with speckle 
tracking echocardiography has been associated with the risk of developing ventricular 
arrhythmias.5, 8 In 988 patients after acute myocardial infarction who were followed-up for a 
median of 28 months, the occurrence of the composite endpoint (SCD, ventricular 
arrhythmias or appropriate ICD shocks) was documented in 34 (3.4%) patients.5 In this 
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population, Ersboll et al showed that LV global longitudinal strain (GLS) was independently 
associated with the occurrence of the composite endpoint (hazard ratio [HR]: 1.24; 95% 
confidence interval [CI]: 1.10 to 1.40; p=0.0004) (Figure 1). More specifically, regional LV 
longitudinal strain may better characterize the function of the infarct core, border zone and 
remote zone. Using regional LV longitudinal strain, Ng et al evaluated the prognostic value of 
the longitudinal strain of the border zone in 424 patients with ischemic heart disease 
recipients of an ICD.8 The infarct core zone was defined by LV segments with a value of 
regional longitudinal strain of >-5% and the border zone was formed by all the surrounding 
segments immediately adjacent to the infarct segments. During a median follow-up of 24 
months, 95 (22%) patients had appropriate ICD shocks. When the population was 
dichotomized according to the medial value of longitudinal strain of the border zone (≤-9.9% 
versus >-9.9%), patients with values ≤-9.9% (more preserved function) showed less 
frequently appropriate ICD shocks compared with their counterparts (8%, 11% and 14% at 1, 
2 and 3 years follow-up compared with a respective  15%, 21% and 25%, respectively; log-
rank p=0.008).8 On multivariate analysis, each 1% deterioration in longitudinal strain of the 
LV segments of the border zone was independently associated with 1.22 increased HR of 
having ventricular arrhythmias (95% CI 1.09-1.36; p<0.001).  
In addition, the dispersion of the LV mechanical activation measured with speckle tracking 
echocardiography as the standard deviation of the time to peak longitudinal strain of 16 LV 
segments has been proposed as a surrogate to characterize the tissue heterogeneity that 
may predispose to ventricular arrhythmias (Figure 1).6 In a prospective multi-center study 
including 569 patients who survived >40 days after an acute myocardial infarction (47% with 
ST-segment elevation myocardial infarction), the prognostic value of LV mechanical 
dispersion was assessed.6 During a follow-up of 30 months, 15 (3%) patients presented with 
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ventricular arrhythmias. Each 10 ms increase in LV mechanical dispersion was associated 
with increased risk of ventricular arrhythmias at follow-up (HR 1.7, 95% CI 1.2–2.5; p<0.01), 
whereas LV GLS was not significantly associated. In the study by Ersboll et al above 
mentioned, LV mechanical dispersion was also associated with increased risk of ventricular 
arrhythmias (each 10 ms increase: HR 1.15, 95% CI 1.01–1.31; p=0.032).5  It has been 
suggested that LV mechanical dispersion may become more relevant than LV GLS in 
populations with a history of myocardial infarction.7 Indeed, LV mechanical dispersion may 
be a consequence of scar tissue formation and collagen deposition and may promote itself 
ongoing ventricular remodeling and fibrosis, particularly in the infarct and border zones. In 
206 patients with prior myocardial infarction (median myocardial infarction age, 6.2 years), 
increasing LV mechanical dispersion was associated with increased risk of ventricular 
arrhythmias independently of LV GLS (HR 1.12, 95% CI 1.06-1.18; p<0.001).7 
Furthermore, in ischemic heart failure patients, assessment of myocardial ischemia and 
viability with dobutamine stress echocardiography is of importance and has been associated 
with the occurrence of ventricular arrhythmias. In 90 patients with ischemic heart disease 
and treated with an ICD for primary or secondary prevention, the presence of inducible 
ischemia during dobutamine stress echocardiography was associated with 2-fold increased 
risk of death or appropriate ICD therapy at follow-up (95% CI, 1.2–3.5; p<0.001).22 
Revascularization of ischemic myocardium has demonstrated to reduce the risk of 
arrhythmic events.23  
Non-ischemic cardiomyopathies  
Reduction of LVEF in the absence of significant coronary artery disease, valvular heart 
disease, hypertension or congenital heart disease, defines non-ischemic cardiomyopathy and 
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can be caused by primary disorders of the myocardium or secondary to systemic diseases 
that cause myocardial damage.24 The most frequent form is dilated cardiomyopathy, with a 
yearly incidence of 0.57 cases/100 000 per year among children and 7 cases/100 000 per 
year among adults.24 Familial dilated cardiomyopathy may be observed in 20-48% and 
frequently has an autosomal-dominant inheritance. Myocarditis, toxicity-related myocardial 
damage, metabolic disturbance storage diseases and infiltrative diseases are other causes of 
non-ischemic cardiomyopathy. Patients with non-ischemic cardiomyopathy have an 
increased risk of ventricular arrhythmias and SCD and the efficacy of ICD to improve long-
term outcome in primary prevention has been shown in several randomized trials.25, 26 
Evaluation of arrhythmogenic substrate with CMR and echocardiography may refine risk 
stratification in patients with non-ischemic cardiomyopathy. Replacement fibrosis assessed 
with LGE CMR and mechanical and electrical tissue heterogeneity using speckle tracking 
echocardiography have been associated with increased risk of ventricular arrhythmias and 
SCD (Table 2).27-42 
The association between the presence of LGE (replacement fibrosis) and risk of SCD, aborted 
SCD or appropriate ICD therapy for ventricular tachycardia was demonstrated in a recent 
meta-analysis of 7 studies including 1194 patients with non-ischemic cardiomyopathy (odds 
ratio 5.32; 95% CI 3.45-8.2; p<0.001).43 Each type of non-ischemic cardiomyopathy may 
show a distinct spatial distribution of replacement fibrosis on LGE CMR (Figure 2). In dilated 
cardiomyopathy, 30% of patients may show septal mid-wall fibrosis.32 In myocarditis, LGE 
distribution is typically epicardial, particularly in the inferolateral wall or septum.35 Cardiac 
sarcoidosis and Anderson-Fabry’s disease typically show midwall LGE in the basal 
inferolateral segments while in Duchenne muscular dystrophy the distribution of LGE is 
typically subepicardial affecting the lateral segments.37-39 Diffuse and patchy distribution of 
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LGE or more typically circumferential subendocardial distribution of LGE can be observed in 
cardiac amyloidosis.44 In contrast to ischemic cardiomyopathy, the different studies 
evaluating the role of LGE CMR for risk stratification of patients with non-ischemic 
cardiomyopathy have focused mainly on the presence of LGE (Table 2).27-42  Furthermore, 
LGE CMR permits characterization of the border zone which may include isthmus sites of 
ventricular tachycardia in non-ischemic cardiomyopathy patients.45  
Few studies have associated echocardiographic global LV longitudinal strain and mechanical 
dispersion (as surrogates of myocardial fibrosis and slow conduction) with ventricular 
arrhythmias and SCD.41, 42 In 100 patients with sarcoidosis who were followed-up during a 
median of 35 months, Joyce et al demonstrated that global LV longitudinal strain was 
independently associated with a 1.4-fold increased risk for the combined end point (all-
cause mortality, heart failure hospitalization, device implantation, new arrhythmias and 
development of cardiac sarcoidosis).41 In 94 patients with non-ischemic dilated 
cardiomyopathy, Haugaa and colleagues demonstrated the prognostic value of global LV 
longitudinal strain and mechanical dispersion.42 During a median follow-up, 13% of patients 
presented with sustained ventricular tachycardia or cardiac arrest. Each 1% worsening in 
global LV longitudinal strain and each 10 ms increase in mechanical dispersion were both 
independently associated with a 1.2-fold increased risk of ventricular arrhythmias or cardiac 
arrest (p=0.002 for both).42 
Inheritable arrhythmogenic diseases  
Hypertrophic cardiomyopathy is the most frequent genetic heart disease, usually caused by 
mutations of genes encoding sarcomeric proteins, transmitted with an autosomal dominant 
inheritance but with incomplete penetrance and variable expression.46, 47 The diagnosis is 
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based on the presence of abnormally increased LV wall thickness (≥15 mm) by any imaging 
modality nor explained by loading conditions and in the absence of other diseases associated 
with LV hypertrophy (Figure 3).48 The arrhythmogenic substrate is characterized by myocyte 
disarray and myocardial fibrosis while microvascular dysfunction, ischemia and sympathetic 
innervation disturbances that may influence the arrhythmogenic substrate triggering the 
occurrence of ventricular arrhythmias. Non-sustained ventricular arrhythmias have been 
reported in 25% of patients during ambulatory electrocardiographic monitoring49 and the 
prevalence increases with LV wall thickness and the presence of replacement fibrosis on LGE 
CMR.50 The annual incidence of SCD is 0.8%, with the highest prevalence among young 
patients.51, 52 The 2014 European Society of Cardiology guidelines on the diagnosis and 
management of patients with hypertrophic cardiomyopathy proposed an algorithm to 
calculate the risk of SCD.46 Maximum LV wall thickness, maximum LV outflow tract gradient 
(at rest and during Valsalva manoeuvres) and left atrial size were included in the algorithm 
and can be assessed with echocardiography. Cine CMR can also quantify LV wall thickness 
and left atrial dimensions however quantification of the LV outflow tract obstruction is not 
routinely assessed. Replacement fibrosis on LGE CMR has been described in 65% of patients 
(range 33-84%) and is typically distributed following a patchy mid-wall pattern in areas of 
hypertrophy and at the insertion points of the right ventricle (Figure 3).53 In a recent large 
registry including 1293 patients with hypertrophic cardiomyopathy, each 10% increase in 
LGE was independently associated with increased risk of SCD events (HR 1.46, 95% CI 1.12-
1.92; p=0.002).54 The addition of LGE to a SCD event risk model resulted in enhanced 
integrated discrimination improvement (56.5%) and net reclassification improvement 
(12.9%). A recent meta-analysis of 6 studies including 3067 patients with hypertrophic 
cardiomyopathy evaluated with LGE CMR (54% showing LGE) demonstrated that the 
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incidence of SCD events was significantly increased among those patients with LGE 
compared with patients without (odds ratio 2.52, 95% CI 1.44-4.4; p=0.001).55 However, 
meta-regression analysis showed that the extent of LGE was not significantly associated with 
SCD events risk (p=0.35) probably due to the inclusion of 5 studies that included patients 
with a mean LGE extent <10%.54, 56-59  
Speckle tracking echocardiographic LV strain analysis has demonstrated to correlate with the 
amount of replacement fibrosis in hypertrophic cardiomyopathy patients and therefore it 
could be hypothesized that the assessment of LV strain may be also associated with 
increased risk of ventricular arrhythmias (Figure 4).60 In 92 hypertrophic cardiomyopathy 
patients undergoing ICD implantation, Debonnaire et al showed that global LV longitudinal 
strain measured with speckle tracking echocardiography was independently associated with 
occurrence of appropriate ICD therapy at follow-up (HR 1.15, 95% CI 1.02-1.3; p=0.03).61 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is also an autosomal dominant 
inheritance disease with variable penetrance and phenotype expression characterized by 
replacement of ventricular myocardium by fibrous and fatty tissue.62 Sustained 
monomorphic ventricular tachycardia with left bundle branch block morphology is the most 
frequent arrhythmia and is usually observed at advanced stages of the disease whereas 
ventricular fibrillation may occur at any phase of the disease. The imaging criteria that 
suggest ARVC include right ventricular dilatation and regional right ventricular wall motion 
abnormalities (aneurysms).62 CMR is considered the reference standard for right ventricular 
volumes quantification and its high spatial resolution permits better identification of right 
ventricular aneurysms (Figure 5). Two-dimensional echocardiography provides several 
measurements to accurately estimate the RV dimensions, and with the use of intravenous 
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contrast, the regional wall motion abnormalities can be better visualized. However, it has 
been shown that echocardiography had lower diagnostic performance compared with 
CMR.63 Although assessment of LGE with CMR in ARVC is challenging due to the thin right 
ventricular walls and the low specificity (as it can also be observed in other 
cardiomyopathies that resemble ARVC such as cardiac sarcoidosis), right ventricular LGE can 
be observed in 88% of patients.64 In a recent study including 69 patients with ARVC, the 
presence of abnormalities on CMR (right ventricular dilatation, wall motion abnormalities, 
LGE or LV and biventricular involvement) was associated with development of ventricular 
arrhythmias; specifically the presence of right ventricular LGE was only observed in patients 
presenting with arrhythmic events.65 Assessment of global LV longitudinal strain with speckle 
tracking echocardiography has demonstrated that LV involvement in ARVC patients 
demonstrated by impaired global LV longitudinal strain was independently associated with 
the occurrence of ventricular tachycardia, SCD and appropriate ICD therapies.66 If confirmed 
in larger studies, the results may have important implications since in many ARVC patients 
LV involvement occurs at a late stage of the disease and earlier detection of LV dysfunction 
may identify the patients who may potentially benefit from an ICD. 
Finally, primary electric disorders or channelopathies, such as long QT syndrome, Wolff-
Parkinson-White syndrome or Brugada syndrome are characterized by preserved LVEF 
without structural abnormalities. The prolongation of the action potential and repolarization 
that occur in these disorders may increase the risk of afterdepolarizations and polymorphic 
ventricular arrhythmias. Speckle tracking echocardiography has demonstrated to identify 
mechanical disturbances as a consequence of the electric derangements.67 Particularly, in 
long QT syndrome, LV mechanical dispersion (calculated as the differences in time to 
regional peak strain measured in the sub- and the midmyocardium) was longer in 
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symptomatic patients compared with asymptomatic carriers (45±13 ms vs. 27±12 ms and 
46±22 ms vs. 26±21 ms, respectively; p<0.001 for both).67 There is limited literature on the 
role of CMR in this patient group. In a cohort of 81 patients with genetically positive Brugada 
syndrome, CMR demonstrated changes in RV ejection fraction and volumes compared to 
patients without the mutation.68 
Conclusions  
Left ventricular ejection fraction assessed with any imaging technique remains as an 
important criterion to identify the patients at risk of having ventricular arrhythmias or SCD.3 
However, a significant proportion of patients with reduced LVEF who receive an ICD for 
primary prevention may not experience an appropriate therapy. In contrast, patients with 
relatively preserved LVEF or patients without structural heart disease and normal LVEF may 
experience life-threatening arrhythmias. Advanced echocardiographic imaging techniques 
evaluating the active deformation of the myocardium provided the incremental value over 
LVEF for risk stratification in a variety of patients with cardiac disease. Cardiac magnetic 
resonance and particularly, the use of LGE have provided further characterization of the 
arrhythmogenic substrate with important prognostic and therapeutic implications. Current 
guidelines support the role of these imaging techniques to accurately assess patients at risk 
of SCD.  
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Table 1. Cardiac magnetic resonance and echocardiographic parameters (beyond LVEF) associated with ventricular arrhythmias in ischemic 
heart failure patients. 
Imaging technique Parameter Evidence 
LGE CMR Infarct size Increasing number of LV segments with transmural myocardial 
infarction was associated with increased risk of having 
appropriate ICD shock (HR 1.48, 95% CI 1.18-1.84, p=0.001).11 
Border zone Each 10 g increase in peri-infarct zone was independently 
associated with the occurrence of ventricular arrhythmias (HR 
1.49, 95% CI 1.01-2.20; p=0.04).13 
Conduction channels Identifiable conduction channels were more frequent among 
patients with ventricular arrhythmias.17 
Balanced steady-state free 
precession CMR 
Iron deposits-haemorrhage The presence of hypointense areas within the infarct core, 
indicating iron deposits or haemorrhage has incremental value to 
LVEF to predict the occurrence of ventricular arrhythmias.18 
Vasodilator stress CMR Inducible ischemia The presence of reversible perfusion defects has prognostic value 
complementary to LGE for prediction of cardiac death 19 
Echocardiography- Speckle 
tracking 
LV GLS Reduced magnitude of LV GLS was associated with 1.24-fold 
increase risk of ventricular arrhythmias (95% CI 1.10 to 1.40; 
p=0.0004) in 988 patients with acute STEMI.5 
LV Longitudinal strain – border zone Each 1% deterioration in longitudinal strain of the LV segments of 
the border zone was independently associated ventricular 
arrhythmias (HR 1.22; 95% CI 1.09-1.36; p<0.001) in 424 patients 
with chronic IHD.8 
LV mechanical dispersion Each 10 ms increase in LV mechanical dispersion has been 
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associated with increased risk of arrhythmias in: 
• 569 patients with acute STEMI/non-STEMI (HR 1.7)6 
• 988 patients with acute STEMI (HR 1.15)5 
• 206 patients with chronic IHD (HR 1.12)7 
Dobutamine stress 
echocardiography 
Inducible ischemia The presence of inducible ischemia was associated with 
ventricular arrhythmias (HR 2.1, 95% CI 1.2–3.5; p<0.001) in 90 
patients with chronic IHD.22  
 
Abbreviations: CI: confidence interval; GLS: global longitudinal strain; HR: hazard ratio; IHD: ischemic heart disease; LV: left ventricular; STEMI: 
ST-segment elevation acute myocardial infarction. 
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Table 2.  Assessment of arrhythmogenic substrate with CMR and advanced echocardiography in non-ischemic cardiomyopathies. 
Imaging technique Study No. Cardiomyopathy Parameter Evidence 
LGE CMR 
Wu et al27 65 DCM Presence of LGE Patients with LGE presented more frequently with cardiac death or 
appropriate ICD therapy (22% vs. 8%, p=0.03). 
Presence of LGE was independently associated with heart failure 
hospitalization, cardiac death or appropriate ICD therapy (HR 8.2, 95% CI 
2.2-30.9; p=0.002). 
Iles et al28 61 NA Presence of LGE Patients with LGE showed significantly higher rates of appropriate ICD 
therapies compared with patients without LGE (29% vs. 0%, p<0.001). 
Lehrke et al29 184 DCM Presence of LGE 
 
 
Extent of LGE 
Presence of LGE was associated with 3.4-fold increased risk of combined 
end point (cardiac death, appropriate ICD therapy and heart failure 
hospitalization) (95% CI 1.26-9, p=0.015). 
Patients with LGE extending ≥4.4% of the LV mass showed an increased 
rate in the combined end point. 
Gao et al30 65 Myocarditis (n=8) 
Sarcoidosis (n=6) 
Chemotherapy (n=3) 
ARVC (n=1) 
NA (n=47) 
Extent of LGE Patients with scar mass above the median value (20.8 g) showed higher 
cumulative risk of appropriate ICD therapy, survived cardiac arrest or SCD 
than their counterparts (HR 1.8, 95% CI 0.4-7.6; p=0.4). 
Muller et al31 185 DCM (n=102) 
Myocarditis (n=65) 
HCM (n=15) 
Storage disease (n=3) 
Presence of LGE Patients with LGE showed higher cumulative 3-year event rates 
(composite end point including appropriate ICD and sustained ventricular 
arrhythmias) than their counterparts (67% vs. 27%; p=0.021). However, 
presence of LGE was not independently associated with outcome (HR 1.1, 
95% CI 0.6-2.1; p=0.67). 
Gulati et al32 472 DCM Presence of LGE 
Extent of LGE 
Patients with midwall LGE were 5 times more likely to present with SCD 
or aborted SCD compared with patients without (29.6% vs. 7%). Each 1% 
increment in LGE extent was independently associated with arrhythmic 
outcome (HR 1.10, 95% CI 1.05-1.16; p<0.001). 
Neilan et al33 162 NA 
(infiltrative cardiomyopathy 
excluded) 
Presence of LGE 
Extent of LGE 
Presence of LGE (HR 14, 95% CI 4.4-45.6; p<0.001) and each 1% increment 
in LGE extent (HR 1.17, 95% CI 1.12-1.22; p<0.0001) were strongly 
associated with appropriate ICD therapy or non-heart failure cardiac 
death. 
Masci et al34 228 DCM 
Chemotherapy (n=7) 
Presence of LGE Patients with LGE showed 8.3-fold higher risk of aborted SCD versus 
patients without LGE (95% CI 1.66-41.55; p=0.01). 
Grün et al35 222 Myocarditis Presence of LGE LGE was more frequently observed among patients who presented with 
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Extent of LGE SCD compared with patients without event (100% vs. 43%; p<0.001). 
Presence of LGE was independently associated with cardiac death (HR 
12.8; p<0.01). 
Mello et al36 41 Chagas cardiomyopathy Presence of LGE 
Extent of LGE 
The presence of ≥2 LV segments with transmural scar was independently 
associated with ventricular arrhythmias (relative risk 4.1; 95% CI 1.06-
15.68;p=0.04). 
Kramer et al37 57 Anderson-Fabry’s disease Presence of LGE 
Progression of 
LGE 
Only patients with LGE presented with ventricular arrhythmic events. 
Annual increase in fibrosis (LGE) was the only independent predictor of 
ventricular arrhythmias (p=0.038). 
Florian et al38 88 Duchnne and Becker muscular 
dystrophies 
Presence of LGE Presence of transmural LGE was independently associated with heart 
failure hospitalizations or ventricular arrhythmias (HR 2.89, 95% CI 1.09-
7.68; p=0.033). 
Greulich et al39 155 Sarcoidosis Presence of LGE Patients with LGE had 31.6-fold increased risk of presenting with death, 
aborted SCD or appropriate ICD therapy (p=0.0014). 
Murtagh et al40 205 Sarcoidosis Presence of LGE 
Extent of LGE 
The annualized rate of death or ventricular tachycardia was significantly 
higher among patients with LGE compared with patients without (4.93% 
vs. 0.24%, p<0.05). Each 1% increase in LGE extent resulted in 8% increase 
in the hazard of death or ventricular tachycardia. 
Speckle tracking 
echocardiography 
Joyce et al41 100 Sarcoidosis Global LV 
longitudinal strain 
Global LV longitudinal strain was independently associated with 1.4-fold 
increased risk of composite end point (including arrhythmias). 
Haugaa et al42 94 DCM Global LV 
longitudinal strain 
Mechanical 
dispersion 
Each 1% worsening in global LV longitudinal strain was independently 
associated with ventricular arrhythmias, SCD and appropriate ICD therapy 
(HR 1.26, 95% CI 1.03-1.54; p=0.02). 
Each 10 ms increment in mechanical dispersion was associated with a 
1.20 increased risk for ventricular arrhythmias, SCD and appropriate ICD 
therapy (95% CI 1.03-1.4; p=0.02). 
 
Abbreviations: ARVC: arrhythmogenic right ventricular cardiomyopathy; DCM: dilated cardiomyopathy; CI: confidence interval; CMR: cardiac 
magnetic resonance; HCM: hypertrophic cardiomyopathy; HR: hazard ratio; LGE: late gadolinium enhancement; LV: left ventricular; NA: not 
available; SCD: sudden cardiac death.  
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Figure 1. Cardiac magnetic resonance and echocardiographic speckle tracking analysis  for 
risk stratification of patients with ischemic heart disease. Panels A and B show transmural 
myocardial scar in the apical septal and anteroseptal segments (arrows) and subendocardial 
scar in the mid inferoseptal segment. On 2-dimensional speckle tracking echocardiography, 
the magnitude of global longitudinal strain is -10.6% (panel C). The LV apical segments show 
positive values and are color-coded in blue indicating lengthening (correlating with the area 
of transmural scar). Panel D shows significant mechanical dispersion (65.7 ms) based on the 
standard deviation of time to peak longitudinal strain of 17 segments.  The most delayed 
areas coincide with the areas with scar and impaired longitudinal strain. 
 
  
29 
 
Figure 2. Patterns of late gadolinium contrast enhancement in non-ischemic 
cardiomyopathies. Septal mid-wall late gadolinium enhancement (arrow) is typically 
observed in dilated cardiomyopathy (A). Mid-wall late gadolinium enhancement of the basal 
inferolateral wall (arrow) in a patient with cardiac sarcoidosis (B). Patchy mid-wall late 
gadolinium enhancement of the hypertrophic septum at the level of the right ventricular 
junction (arrow) is typical of hypertrophic cardiomyopathy (C). In cardiac amyloidosis (D), the 
pattern of late gadolinium enhancement is characterized by circumferential subendocardial 
distribution (arrows).  
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Figure 3. Hypertrophic cardiomyopathy. Panel A shows left ventricular (LV) hypertrophy 
with >15 mm thickness of the septal and lateral walls. Panel B shows late gadolinium 
enhanced cardiac magnetic resonance of a patient with hypertrophic cardiomyopathy and 
delayed enhancement in the septum, at the insertion of the right ventricle (arrow). 
 
  
31 
 
Figure 4. Risk stratification of patients with hypertrophic cardiomyopathy using two-
dimensional speckle tracking echocardiography. Example of a patient with hypertrophic 
obstructive cardiomyopathy with asymmetric septal hypertrophy and systolic anterior 
motion of the mitral valve (A). On echocardiographic speckle tracking analysis, the 
magnitude of global left ventricular longitudinal strain (GLS) is -13.8% (B). The study by 
Debonnaire et al showed that patients with a left ventricular GLS ≥-14% had higher rates of 
appropriate implantable cardioverter defibrillator (ICD) therapy compared with patients with 
more preserved GLS (<-14%) (C). Reproduced with permission from Debonnaire et al.61 
 
  
32 
 
Figure 5. Cardiac magnetic resonance in arrhythmogenic right ventricular cardiomyopathy. 
Example of a patient who presented with ventricular tachycardia. On cine cardiac magnetic 
resonance, the 4-chamber view shows a dilated right ventricle, with depressed ejection 
fraction (35%) and areas of dyskinesia (arrow, A). On late gadolinium contrast enhanced 
cardiac magnetic resonance, the areas with dyskinesia show hyperenhancement (arrow, B). 
 
 
 
